Table 1 Baseline demographics for the intent-to-treat populations from the three pivotal migraine prevention trials
Pivotal Topiramate Trials | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Silberstein 2004 [3] | Brandes 2004 [4] | Diener 2004 [5] | Pooled | ||||||
Placebo | Topiramate 100 mg/d | Placebo | Topiramate 100 mg/d | Placebo | Topiramate 100 mg/d | Placebo | Topiramate 100 mg/d | P value* | |
No. of Patients (completers) | 115 (69) | 125 (83) | 114 (63) | 120 (63) | 143 (99) | 139 (94) | 372 (231) | 384 (240) | |
Age, Mean ± SD (yrs) | 40.4 ± 11.5 | 40.6 ± 11.0 | 38.3 ± 12.0 | 39.1 ± 12.6 | 40.4 ± 10.1 | 39.8 ± 10.9 | 39.8 ± 11.1 | 39.8 ± 11.5 | 0.939 |
Female, n (%) | 103 (90%) | 112 (90%) | 94 (82%) | 109 (91%) | 109 (76%) | 110 (79%) | 306 (82%) | 331 (86%) | 0.160 |
Caucasian, n (%) | 107 (93%) | 117 (94%) | 101 (89%) | 108 (90%) | 127 (89%) | 122 (88%) | 335 (90%) | 347 (90%) | 0.965 |